RecruitingNCT07057765

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity

Sponsor

Ain Shams University

Enrollment

40 participants

Start Date

May 5, 2025

Study Type

OBSERVATIONAL

Conditions

DLBCL - Diffuse Large B Cell Lymphoma Markers of Inflammation

Summary

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether certain blood test measurements — including CRP (a marker of inflammation), albumin (a protein level), and two scores derived from these — can predict how well patients with a specific type of lymphoma (DLBCL) will respond to standard chemotherapy treatment. **You may be eligible if...** - You are between 18 and 65 years of age - You have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL), confirmed by a tissue sample - You have not received any prior treatment for this lymphoma - You are scheduled to receive standard chemotherapy (R-CHOP) - You are well enough to perform basic daily activities (ECOG performance status 0-2) **You may NOT be eligible if...** - You have already received treatment for DLBCL - You have serious other illnesses or organ problems - You are pregnant or breastfeeding - You have a different subtype of lymphoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGObservational Assessment of Standard R-CHOP Treatment

Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.